Payment overview · 2025
General Payments
$4,339.42
121 reported records · 22 companies
Healthcare provider profile · identity verified
Rodrigo E Morales, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · WARNER ROBINS, GA · NPI 1780609867
Verified facts
What the public records show
CMS Open Payments records show Rodrigo E Morales, M.D. received $4,339.42 in general payments during 2025 across 121 reported records.
Olympus Corporation of the Americas accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ofev, Opsumit, Trelegy Ellipta, Wakix, Xywav.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 691 claims for Trelegy Ellipta by this doctor in 2024.
HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wakix by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xywav by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Olympus Corporation of the Americas | Unresolved — no canonical attribution shown | $1,675.44 | 38.6% | 13 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $264.30 | 6.1% | 7 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $256.37 | 5.9% | 12 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $229.15 | 5.3% | 12 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $221.65 | 5.1% | 9 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $196.11 | 4.5% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $175.31 | 4.0% | 11 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $156.25 | 3.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $147.38 | 3.4% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $128.67 | 3.0% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $128.58 | 3.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $111.50 | 2.6% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $109.51 | 2.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $105.85 | 2.4% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $98.49 | 2.3% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.01 | 2.2% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $94.52 | 2.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.72 | 1.0% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $38.08 | 0.9% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $24.04 | 0.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.74 | 0.5% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $18.75 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,614.01 | 111 |
| Travel and Lodging | $1,625.42 | 9 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Spiration Valve System Normalized: spiration valve system |
Device | Olympus Corporation of the Americas | $744.39 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $284.92 | 9 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $264.30 | 7 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $256.37 | 12 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $229.15 | 12 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $221.65 | 9 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $196.11 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $175.31 | 11 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $128.58 | 5 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $105.85 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $98.49 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $97.01 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $94.52 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $90.02 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.95 | 4 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $72.37 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $60.72 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.72 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $40.40 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $38.08 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OFEV ofev |
2025 | Ofev | 2024 | 42 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 691 | exact normalized | Medicare Part D |
| WAKIX wakix |
2025 | Wakix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
70 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
691 | 151 |
| HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference |
2025 | WAKIX open payments reported associated product |
CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076 |
Wakix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 691 | 151 |
| Fluticasone Propionate | Fluticasone Propionate | 552 | 231 |
| Azelastine Hcl | Azelastine Hcl | 548 | 238 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 519 | 191 |
| Montelukast Sodium | Montelukast Sodium | 463 | 112 |
| Theophylline Er | Theophylline Anhydrous | 216 | 45 |
| Prednisone | Prednisone | 169 | 70 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 135 | 36 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 128 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 31 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 116 | 25 |
| Azithromycin | Azithromycin | 112 | 43 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 84 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 81 | 18 |
| Modafinil | Modafinil | 81 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 73 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 29 |
| Spiriva Respimat | Tiotropium Bromide | 69 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 68 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 63 | 17 |
| Metformin Hcl | Metformin Hcl | 62 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 61 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 58 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 57 | 18 |
| Furosemide | Furosemide | 57 | 17 |
| Eliquis | Apixaban | 54 | 13 |
| Gabapentin | Gabapentin | 54 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 17 |
| Famotidine | Famotidine | 50 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 11 |
| Allopurinol | Allopurinol | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 43 |
| Omeprazole | Omeprazole | 45 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 14 |
| Ofev | Nintedanib Esylate | 42 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 16 |
| Atenolol | Atenolol | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 34 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | 13 |
| Simvastatin | Simvastatin | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 11 |
| Lisinopril | Lisinopril | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 11 |
| Losartan Potassium | Losartan Potassium | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Roflumilast | Roflumilast | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Wakix | Pitolisant Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Opsumit | Macitentan | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Itraconazole | Itraconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,339.42 · 121 records | Olympus Corporation of the Americas | ACTHAR, AIRSUPRA, Adempas, Arikayce, BREZTRI, Brinsupri, DUPIXENT, FASENRA, Hillrom - Vest System Model 105 Home Care, INSPIRE, JASCAYD, LUMRYZ, NUCALA, OFEV, OPSUMIT, Ohtuvayre, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, Spiration Valve System, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, WAKIX, WINREVAIR, XYWAV, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ofev play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error